Abstract: A compound of formula (I) or a pharmaceutically acceptable derivative thereof, (formula 1) wherein R1, R2, R3, R4, R5, X, m and n are defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.

Abstract: A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

Abstract: A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a lipid covalently linked to an amino acid or peptide coupled to a polyamine group, and a process for the manufacture of the conjugated compound, as well as a complex formed between the conjugated compound and a polyanionic molecule and a pharmaceutical composition containing the conjugated compound or complex. Also described is the use of the conjugated compound or complex in the treatment of infection, cancer or immune disorders or for use in vaccines.

Abstract: A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II:

Abstract: A conjugated compound of Formula I: Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II:

Abstract: A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

Abstract: A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a lipid covalently linked to an amino acid or peptide coupled to a polyamine group, and a process for the manufacture of the conjugated compound, as well as a complex formed between the conjugated compound and a polyanionic molecule and a pharmaceutical composition containing the conjugated compound or complex. Also described is the use of the conjugated compound or complex in the treatment of infection, cancer or immune disorders or for use in vaccines.

Abstract: Disclosed is a novel formulation for the production of a lyophilized plasmid/DNA transfection reagent complex capable of serving as a carrier for additional free plasmids. Upon rehydration, this plasmid/DNA transfection reagent carrier can be used to introduce simultaneously the complexed plasmid and the additional free plasmids into animal cells. This novel formulation can be useful for viral particle production, gene transfer experiments like gene silencing experiments, reporter gene, or integration/selection experiments.

Abstract: A nucleic acid delivery complex is provided which comprises a condensed polypeptide/nucleic acid complex and a cationic lipid wherein the complex comprises (a) a nucleic acid sequence of interest (NOI); and (b) one or more viral nucleic acid packaging polypeptides, or derivatives thereof, said polypeptides or derivatives thereof being (i) capable of binding to the NOI; and (ii) capable of condensing the NOI; and wherein the NOI is heterologous to the polypeptide. Also provided is a method of introducing an NOI into a cell using the delivery vector.

Abstract: The present invention relates to a non-viral delivery vector comprising a liposome, wherein one or more lipids of the liposome are coupled, reversibly or irreversibly, to one or more polymers, and wherein the liposome comprises siRNA.

Abstract: The present invention provides a process for preparing a modified lipid of the formula comprising reacting (I) a compound of the formula; and (ii) a compound of the formula wherein component (ii) is formulated as a liposome; wherein B is a lipid; wherein A is a moiety of interest (MOI) and is a hydrocarbyl group; wherein X is an optional linker group; wherein R1 is H or a hydrocarbyl group; and wherein R2 is a lone pair, H or a hydrocarbyl group. The moiety of interest A may be selected from a carbohydrate moiety, a polymer, a peptide, a glycoprotein, a small biomolecule (such as a folic acid derivative) and a bioconjugate linker.

Abstract: The present invention provides a delivery vehicle for a therapeutic agent comprising a modified lipid and a therapeutic agent; wherein the modified lipid comprises a lipid and a delivery, targeting or stabilising moiety (DTS moiety); wherein the lipid is linked to the DTS moiety via a linker which is stable in biological fluid and which is unstable in defined conditions; and wherein the DTS moiety is linked to the lipid alter formation of a complex of lipid and therapeutic agent.

Abstract: The present invention provides a compound capable of acting as a cationic lipid, the compound comprises a cholesterol group and a carbohydrate moiety.

Abstract: The invention concerns a method for fixing a biological molecule, associated with a specific binding site, on the surface of a support made of silica or metal oxide. The invention also concerns a surface functionalized by the method and the use of such a surface. The method is characterized in that it consists in: functionalizing the surface by cleaning, using at least a solvent or an oxygen plasma or any other process for forming alcohol groups on the support surface, to make it hydrophilic; contacting the biological molecule on said functionalized surface; and functionalizing the support by fixing the biological molecule specific binding site on at least one of the support alcohol groups. The invention is particularly useful in the field of biomedical diagnosis.

Abstract: A nucleic acid delivery complex is provided which comprises a condensed polypeptide/nucleic acid complex and a cationic lipid wherein the complex comprises (a) a nucleic acide sequence of interest (NOI); and (b) one or more viral nucleic acid packaging polypeptides, or derivatives thereof, said polypeptides or derivatives thereof being (i) capable of binding to the NOI; and (ii) capable of condensing the NOI; and wherein the NOI is heterologous to the polypeptide. Also provided is a method of introducing an NOI into a cell using the delivery vector.

Abstract: The invention concerns a method for fixing a biological molecule, associated with a specific binding site, on the surface of a support made of silica or metal oxide. The invention also concerns a surface functionalised by the method and the use of such a surface. The method is characterized in that it consists in: functionalising the surface by cleaning, using at least a solvent or an oxygen plasma or any other process for forming alcohol groups on the support surface, to make it hydrophilic; contacting the biological molecule on said functionalised surface, and functionalising the support by fixing the biological molecule specific binding site on at least one of the support alcohol groups. The invention is particularly useful in the field of biomedical diagnosis.

Abstract: The present invention provides a compound of the formula 1